Terrestrial Bio, a Boston-based developer of needle-free microarray patch (MAP) platforms, has raised $50M in Series C funding led by RA Capital Management. The funding supports a pivot to delivering GLP-1 agonists like semaglutide through dissolvable skin patches that require no refrigeration or sharps. The capital will advance clinical trials, scale manufacturing, and fuel commercialization of the GLP-1 program following a rebrand from Vaxess Technologies.
GLP-1 Surge Drives Patch Investments
The raise aligns with exploding demand for GLP-1 therapies amid adherence challenges from weekly injections. Micron Biomedical has secured $76M+ including a $33M Series A, while Vaxxas raised $90M+ through Series D. Terrestrial differentiates with temperature-stable biomaterials optimized for high-dose biologics like GLP-1, targeting patient comfort over vaccine-centric rivals.
Injection Pain Limits GLP-1 Adherence
GLP-1 agonists face barriers from painful needles and cold chain logistics, hindering access for obesity and diabetes patients. Weekly injections reduce long-term adherence despite blockbuster sales. Current solutions fail to deliver large molecules like peptides without specialized handling.
Dissolvable Patches Match Injection Efficacy
Terrestrial's MAP uses advanced biomaterials for room-temperature stable delivery of biologics, matching subcutaneous bioavailability for semaglutide in preclinical data. A human factors study showed near-universal patient preference.
As study participants noted:
"95% of participants prefer the Vaxess microarray patch to traditional injection devices for GLP-1."
The platform scales to 100M patches annually via in-house GMP manufacturing.
RA Capital Backs Pivot to Therapeutics
RA Capital led the round with participation from Engine Ventures, GHIC, and SiteGround, signaling conviction in Terrestrial's shift from vaccines to GLP-1. This growth-stage capital validates the platform's versatility for peptides, proteins, and mRNA. Investors eye commercialization amid GLP-1 market expansion.
Microneedle Market Scales to $9.5B
The microneedle drug delivery systems market stands at $6.11B in 2024, projected to reach $9.46B by 2030 at 7.4% CAGR per Grand View Research. GLP-1 analogues alone forecast growth from $54.8B in 2024 to $268.4B by 2030 at 30.6% CAGR. Trends favor self-administered, thermostable formats amid biologics boom.
Patch Platform Targets Chronic Diseases
Competitors like ArrayPatch pursue narrower applications with €3M seed, while Daewoong focuses GLP-1 trials via pharma backing. Terrestrial's broad MAP addresses chronic conditions, eliminating cold chains for vaccines and therapies alike.
Clinical Trials Advance GLP-1 Program
Funding enables a new 40,000 sq ft headquarters and automated manufacturing facility at Allston LabWorks in Boston. Plans include clinical trials and commercialization for the GLP-1 patch, building on preclinical success and 95% patient preference data.